Korsana Biosciences, Inc. (KRSA) Fair Value 2026

KRSA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-10-07, Korsana Biosciences, Inc. (KRSA) trades at $31.77. QOC: 5.6/10. Value Trap Risk: 26/100 (LOW). 0/13 models active.

Key Facts

Ticker
KRSA
Price
$31.77
Quality Score
5.6/10
Value Trap Risk
26/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give KRSA?

0 Intrinsic Value Models vs. Current Price ($31.77)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Korsana Biosciences, Inc. (KRSA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Korsana Biosciences, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About KRSA?

0 of 13 models are currently active for KRSA. See which stocks rank higher →

How Does KRSA Rank in Biotechnology?

Among 622 Biotechnology stocks, KRSA ranks #205 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Korsana Biosciences, Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is KRSA a Value Trap?

CirclFi's Value Trap algorithm assigns KRSA a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Korsana Biosciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Korsana Biosciences, Inc. is rated at 5.6/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KRSA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Korsana Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

DNTHDianthus Therapeutics, Inc.QOC 5.6IVAInventiva S.A.QOC 5.6KYNBKyntra Bio, Inc.QOC 5.6EQEquillium, Inc.QOC 5.6IRDOpus Genetics, Inc.QOC 5.6ADXNAddex Therapeutics LtdQOC 5.5FLNAFilana Therapeutics, Inc.QOC 4.8MTNBMatinas BioPharma Holdings, Inc.QOC 4.1IDYAIDEAYA Biosciences, Inc.QOC 6.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: DNTH · IVA · KYNB · EQ · IRD · ADXN · FLNA · MTNB · IDYA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to KRSA?

7 companies across all industries closest to KRSA’s Quality of Company score of 5.6/10.

LIONLionsgate Studios Corp.QOC 5.6GPROGoPro, Inc.QOC 5.6BHMBluerock Homes Trust, Inc.QOC 5.6ASBPAspire Biopharma Holdings, Inc.QOC 5.6VGZVista Gold Corp.QOC 5.6APAmpco-Pittsburgh CorporationQOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LION · GPRO · BHM · ASBP · VGZ · AP · NVDA

Where Does KRSA Sit in CirclFi's Biotechnology Rankings?

KRSA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Korsana Biosciences, Inc.’s Valuation?

What is Korsana Biosciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Korsana Biosciences, Inc. (KRSA). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KRSA overvalued or undervalued right now?

At $31.77, 0 of 0 active models suggest KRSA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Korsana Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.6 mean for KRSA?

Korsana Biosciences, Inc.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on KRSA?

CirclFi analyzes KRSA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is KRSA a value trap in 2026?

Korsana Biosciences, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Korsana Biosciences, Inc. (KRSA) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/KRSA/ · Methodology
Primary sources for this KRSA valuation
  • Financial statements: Korsana Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001755237) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KRSA as of ; valuations recomputed .